Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06549855
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-21
Brief Title:
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient MMRd endometrial cancer who wish to preserve fertility
Detailed Description:
Endometrial cancer EC is a prevalent gynecological cancer with an escalating global incidence The standard treatment for endometrial cancer is total hysterectomy and bilateral salpingo-oophorectomy However given the rising incidence of endometrial cancer in younger individuals and the the delay in the age of human reproduction the conservation of endometrial cancer has garnered heightened attention Clinical practice has demonstrated that high-dose progesterone can reverse the lesioned endometrium thereby providing a rationale for the conservative treatment of early-stage endometrial cancer
PD-1 inhibitor has been utilized as a salvage treatment in many cancers including ovarian cancer cervical cancer lung cancer gastric cancer and endometrial cancer As endometrial cancer showed MMRd rates it is assumed to be highly responsive to PD-1 inhibitor treatment Previous literature has reported that the efficacy of progesterone therapy is limited in patients with a MMRd statusHere we want to investigate the feasibility of PD-1 inhibitor combined with progesterone in early stage endometrial cancer patients who want to preserve fertility
PD-1 inhibitor has been utilized as a salvage treatment in many cancers including ovarian cancer cervical cancer lung cancer gastric cancer and endometrial cancer As endometrial cancer showed MMRd rates it is assumed to be highly responsive to PD-1 inhibitor treatment Previous literature has reported that the efficacy of progesterone therapy is limited in patients with a MMRd statusHere we want to investigate the feasibility of PD-1 inhibitor combined with progesterone in early stage endometrial cancer patients who want to preserve fertility
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None